Recombinant Human NT-proBNP Protein Standard (His tag)
Be the first to review this product! Submit a review
|
(0 Publication)
Recombinant Human NT-proBNP Protein Standard (His tag) is a Human Full Length protein, expressed in Escherichia coli, with >80%, suitable for sELISA, SDS-PAGE.
View Alternative Names
Natriuretic peptides B, Brain natriuretic factor prohormone, Gamma-brain natriuretic peptide, Iso-ANP, preproBNP, proBNP, NPPB
- sELISA
Supplier Data
Sandwich ELISA - Recombinant Human NT-proBNP Protein Standard (His tag) (AB316391)
Sandwich ELISA with the capture antibody dilution at 2 ug/mL and detector antibody dilution at 0.5 ug/mL.
- SDS-PAGE
Supplier Data
SDS-PAGE - Recombinant Human NT-proBNP Protein Standard (His tag) (AB316391)
SDS-PAGE analysis of ab316391
Reactivity data
Product details
While the standard is the same as the one provided in the corresponding SimpleStep ELISA Kit, it cannot be treated as the consumable provided with our SimpleStep ELISA Kit due to differences in its concentration calibration.
Abcam guarantee that this protein standard is suitable for use in a sandwich ELISA. Individual results may vary due to differences in technique, laboratory equipment, buffers, and other experimental factors. The detection range provided for this protein standard is based on initial sandwich ELISA validation data.
The protein concentration is the concentration after validation on our sandwich ELISA platform. This Standard protein is guaranteed to work with our Capture and Detector antibodies in sELISA. Please contact our Scientific Support team to know which antibody pair is suitable for this protein.
Sequence info
Properties and storage information
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
NT-proBNP stands important for cardiovascular homeostasis. It does not participate as part of a complex but plays a role on its own. When released into circulation NT-proBNP functions as an indicator of heart performance indirectly reflecting the activity of the active hormone BNP. Blood vessels dilate under BNP influence reducing systemic vascular resistance and central venous pressure which aids in heart function improvement.
Pathways
NT-proBNP interacts significantly within the cardiac stress response pathways. It plays a focus within the natriuretic peptide system interacting with proteins such as BNP and ANP that help regulate fluid balance and blood pressure. These components together influence pathways that modulate hemodynamic stress and sodium excretion ensuring cardiovascular stability under stress conditions.
Specifications
Form
Liquid
General info
Function
Brain natriuretic peptide 32. Cardiac hormone that plays a key role in mediating cardio-renal homeostasis (PubMed : 1672777, PubMed : 17372040, PubMed : 1914098, PubMed : 9458824). May also function as a paracrine antifibrotic factor in the heart (By similarity). Acts by specifically binding and stimulating NPR1 to produce cGMP, which in turn activates effector proteins that drive various biological responses (PubMed : 1672777, PubMed : 17349887, PubMed : 17372040, PubMed : 21098034, PubMed : 25339504, PubMed : 9458824). Involved in regulating the extracellular fluid volume and maintaining the fluid-electrolyte balance through natriuresis, diuresis, vasorelaxation, and inhibition of renin and aldosterone secretion (PubMed : 1914098, PubMed : 9458824). Binds the clearance receptor NPR3 (PubMed : 16870210).. NT-proBNP. May affect cardio-renal homeostasis (PubMed : 17372040). Able to promote the production of cGMP although its potency is very low compared to brain natriuretic peptide 32 (PubMed : 17372040).. BNP(3-32). May have a role in cardio-renal homeostasis (PubMed : 17372040). Able to promote the production of cGMP (PubMed : 17372040).
Sequence similarities
Belongs to the natriuretic peptide family.
Post-translational modifications
The precursor molecule is proteolytically cleaved by the endoproteases FURIN or CORIN at Arg-102 to produce brain natriuretic peptide 32 and NT-proBNP (PubMed:10880574, PubMed:20489134, PubMed:21314817, PubMed:21482747, PubMed:21763278). This likely occurs after it has been secreted into the blood, either during circulation or in the target cells (PubMed:21482747). CORIN also cleaves the precursor molecule at additional residues including Arg-99 and possibly Lys-105 (PubMed:20489134, PubMed:21763278). In patients with heart failure, processing and degradation of natriuretic peptides B occurs but is delayed, possibly due to a decrease in enzyme level or activity of CORIN and DPP4 (PubMed:25339504).. Brain natriuretic peptide 32. Undergoes further proteolytic cleavage by various proteases such as DPP4, MME and possibly FAP, to give rise to a variety of shorter peptides (PubMed:16254193, PubMed:19808300, PubMed:21098034, PubMed:21314817). Cleaved at Pro-104 by the prolyl endopeptidase FAP (seprase) activity (in vitro) (PubMed:21314817). Degraded by IDE (PubMed:21098034). During IDE degradation, the resulting products initially increase the activation of NPR1 and can also stimulate NPR2 to produce cGMP before the fragments are completely degraded and inactivated by IDE (in vitro) (PubMed:21098034).. O-glycosylated on at least seven residues (PubMed:16750161, PubMed:17349887, PubMed:20489134, PubMed:21482747, PubMed:21763278). In cardiomyocytes, glycosylation at Thr-97 is essential for the stability and processing of the extracellular natriuretic peptides B (PubMed:21482747). Glycosylation, especially at Thr-97, may also be important for brain natriuretic peptide 32 stability and/or extracellular distribution (PubMed:21763278). Glycosylation at Thr-97 appears to inhibit FURIN- or CORIN-mediated proteolytic processing, at least in HEK293 cells (PubMed:20489134, PubMed:21763278).
Target data
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com